Compare TPB & BEAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TPB | BEAM |
|---|---|---|
| Founded | 1988 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Tobacco | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 2.7B |
| IPO Year | 2015 | 2019 |
| Metric | TPB | BEAM |
|---|---|---|
| Price | $97.46 | $27.65 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 16 |
| Target Price | ★ $115.00 | $49.13 |
| AVG Volume (30 Days) | 311.5K | ★ 1.6M |
| Earning Date | 06-01-2026 | 05-15-2026 |
| Dividend Yield | ★ 0.28% | N/A |
| EPS Growth | 45.33 | ★ 82.31 |
| EPS | ★ 3.11 | N/A |
| Revenue | ★ $463,062,000.00 | $24,000.00 |
| Revenue This Year | $12.04 | N/A |
| Revenue Next Year | N/A | $35.80 |
| P/E Ratio | $34.48 | ★ N/A |
| Revenue Growth | 28.39 | ★ 33.33 |
| 52 Week Low | $51.48 | $13.53 |
| 52 Week High | $146.90 | $36.44 |
| Indicator | TPB | BEAM |
|---|---|---|
| Relative Strength Index (RSI) | 25.48 | 47.63 |
| Support Level | $96.69 | $25.89 |
| Resistance Level | $107.85 | $29.06 |
| Average True Range (ATR) | 6.36 | 1.91 |
| MACD | -4.47 | -0.00 |
| Stochastic Oscillator | 1.00 | 23.03 |
Turning Point Brands Inc operates as manufacturer, marketer, provider of consumer products that include Other Tobacco Products (OTP) in the U.S. The company offers a wide variety across the OTP spectrum including moist snuff tobacco (MST), loose-leaf chewing tobacco, premium cigarette papers, make- your-own (MYO) cigar wraps, cigars, liquid vapor products, and tobacco vaporizer products. It operates in two segments namely Zig-Zag products and Stoker's products segment. The company generates maximum revenue from the Zig-Zag products segment.
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.